Status:
RECRUITING
OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events
Lead Sponsor:
Amgen
Conditions:
Cardiovascular Disease
Eligibility:
All Genders
50-105 years
Phase:
PHASE3
Brief Summary
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization...
Eligibility Criteria
Inclusion
- Age ≥50 years
- Lp(a)≥ 200 nmol/L during screening
- Multiple atherosclerotic cardiovascular disease risk factors, and/or evidence of atherosclerosis
Exclusion
- Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
- Prior or planned arterial revascularization
- History of major bleeding disorder
Key Trial Info
Start Date :
August 22 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 20 2031
Estimated Enrollment :
11000 Patients enrolled
Trial Details
Trial ID
NCT07136012
Start Date
August 22 2025
End Date
October 20 2031
Last Update
January 8 2026
Active Locations (199)
Enter a location and click search to find clinical trials sorted by distance.
1
Advanced Cardiovascular LLC
Alexander City, Alabama, United States, 35010
2
University of Alabama Birmingham Saint Vincents Birmingham
Birmingham, Alabama, United States, 35205
3
Alliance For Multispecialty Research - Daphne
Daphne, Alabama, United States, 36526
4
Eastern Shore Research Institute
Fairhope, Alabama, United States, 36532